IL278294B2 - HSV-2-DELTA-gD vaccines and methods for their production and use - Google Patents

HSV-2-DELTA-gD vaccines and methods for their production and use

Info

Publication number
IL278294B2
IL278294B2 IL278294A IL27829420A IL278294B2 IL 278294 B2 IL278294 B2 IL 278294B2 IL 278294 A IL278294 A IL 278294A IL 27829420 A IL27829420 A IL 27829420A IL 278294 B2 IL278294 B2 IL 278294B2
Authority
IL
Israel
Prior art keywords
antigen
hsv
recombinant
virus
subject
Prior art date
Application number
IL278294A
Other languages
English (en)
Hebrew (he)
Other versions
IL278294B1 (en
IL278294A (en
Original Assignee
Albert Einstein College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine filed Critical Albert Einstein College Medicine
Publication of IL278294A publication Critical patent/IL278294A/en
Publication of IL278294B1 publication Critical patent/IL278294B1/en
Publication of IL278294B2 publication Critical patent/IL278294B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL278294A 2018-05-01 2019-05-01 HSV-2-DELTA-gD vaccines and methods for their production and use IL278294B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665050P 2018-05-01 2018-05-01
PCT/US2019/030259 WO2019213305A1 (en) 2018-05-01 2019-05-01 HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE

Publications (3)

Publication Number Publication Date
IL278294A IL278294A (en) 2020-12-31
IL278294B1 IL278294B1 (en) 2024-09-01
IL278294B2 true IL278294B2 (en) 2025-01-01

Family

ID=68386663

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278294A IL278294B2 (en) 2018-05-01 2019-05-01 HSV-2-DELTA-gD vaccines and methods for their production and use

Country Status (8)

Country Link
US (2) US20210236625A1 (https=)
EP (1) EP3787680A4 (https=)
JP (2) JP7671982B2 (https=)
CN (1) CN112368017A (https=)
AU (1) AU2019262056B2 (https=)
CA (1) CA3098572A1 (https=)
IL (1) IL278294B2 (https=)
WO (1) WO2019213305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN116497049B (zh) * 2023-05-04 2024-03-22 江苏三仪生物工程有限公司 一种表达犬疱疹病毒gD糖基化蛋白的重组菌及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130028924A1 (en) * 2006-08-28 2013-01-31 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US20150232812A1 (en) * 2000-01-21 2015-08-20 Biovex Limited Herpes virus strains
US20170202952A1 (en) * 2014-03-03 2017-07-20 Albert Einstein College Of Medicine, Inc Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150232812A1 (en) * 2000-01-21 2015-08-20 Biovex Limited Herpes virus strains
US20130028924A1 (en) * 2006-08-28 2013-01-31 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US20170202952A1 (en) * 2014-03-03 2017-07-20 Albert Einstein College Of Medicine, Inc Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Also Published As

Publication number Publication date
IL278294B1 (en) 2024-09-01
US12150986B2 (en) 2024-11-26
JP2025032104A (ja) 2025-03-11
AU2019262056A1 (en) 2020-10-29
US20230293674A1 (en) 2023-09-21
IL278294A (en) 2020-12-31
AU2019262056B2 (en) 2025-10-02
JP7671982B2 (ja) 2025-05-07
EP3787680A4 (en) 2022-06-22
CA3098572A1 (en) 2019-11-07
WO2019213305A1 (en) 2019-11-07
US20210236625A1 (en) 2021-08-05
EP3787680A1 (en) 2021-03-10
JP2021522854A (ja) 2021-09-02
CN112368017A (zh) 2021-02-12

Similar Documents

Publication Publication Date Title
EP3294329B1 (en) Novel baculovirus vectors and methods of use
Warfield et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents
US20150322115A1 (en) Means and methods for treating cmv
Legrand et al. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes
IL278294B2 (en) HSV-2-DELTA-gD vaccines and methods for their production and use
Jenkins et al. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus
CN113226364A (zh) 组合物和方法
US20230372474A1 (en) Recombinant hvt and uses thereof
CA1273884A (en) Process for the preparation of a herpes antigen, an agent suitable for this and a process for its preparation, and the use of this antigen
He et al. Baculovirus vector as a delivery vehicle for influenza vaccines
CN105274142B (zh) 复制型重组人55型腺病毒载体及其制备方法和应用
JP2021522854A5 (https=)
Valley-Omar et al. Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
Dimier et al. Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice
CN121752290A (zh) Dev作载体的禽流感h9疫苗
TWI908952B (zh) 具有提升免疫原性之經修飾副痘病毒（一）
CN104726416B (zh) 提供流感病毒异源保护的病毒样颗粒及其方法和应用
Jamour et al. Construction of a single-cycle replication recombinant infectious laryngotracheitis virus lacking the glycoprotein H gene and evaluation of its role in viral entry and infectivity
JP2002017370A (ja) 遺伝子組換えワクシニアウイルスワクチン
WO2011099541A1 (ja) 組換えウイルスの製造方法
Lin et al. Recent patents on the baculovirus systems
CA3202009A1 (en) Modified parapoxvirus having increased immunogenicity
US20250325657A1 (en) Modified vaccinia ankara (mva) vaccine
Somboonthum et al. Rapid and efficient introduction of a foreign gene into bacterial artificial chromosome-cloned varicella vaccine by Tn7-mediated site-specific transposition
CN112481222B (zh) 一种条件复制型重组单纯疱疹病毒、疫苗及其应用